{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:57:10Z","timestamp":1789084630505,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"47","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007655","name":"Aichi Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2025,12,9]]},"DOI":"10.1038\/s41388-025-03605-8","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T07:58:42Z","timestamp":1761033522000},"page":"4576-4586","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Meflin is a druggable target using antibody-drug conjugates in progressive osteosarcoma"],"prefix":"10.1038","volume":"44","author":[{"given":"Nobutoshi","family":"Esaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoka","family":"Sakoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Miyai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4363-3161","authenticated-orcid":false,"given":"Yasuyuki","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirai","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2606-059X","authenticated-orcid":false,"given":"Makoto","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoe","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3666-0556","authenticated-orcid":false,"given":"Yukihiro","family":"Shiraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8266-3235","authenticated-orcid":false,"given":"Shinji","family":"Mii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9850-6047","authenticated-orcid":false,"given":"Jiro","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2763-1414","authenticated-orcid":false,"given":"Shino","family":"Manabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohisa","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7511-6388","authenticated-orcid":false,"given":"Yoshihiro","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9206-6116","authenticated-orcid":false,"given":"Atsushi","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"3605_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"3605_CR2","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.3390\/cancers13071683","volume":"13","author":"E Thebault","year":"2020","unstructured":"Thebault E, Piperno-Neumann S, Tran D, Pacquement H, Marec-Berard P, Lervat C, et al. Successive osteosarcoma relapses after the first line O2006\/Sarcome-09 Trial: what can we learn for further phase-II trials?. Cancers. 2020;13:1683.","journal-title":"Cancers"},{"key":"3605_CR3","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.ejca.2010.11.036","volume":"47","author":"H Gelderblom","year":"2011","unstructured":"Gelderblom H, Jinks RC, Sydes M, Bramwell VH, van Glabbeke M, Grimer RJ, et al. European Osteosarcoma Intergroup. Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. Eur J Cancer. 2011;47:895\u2013902.","journal-title":"Eur J Cancer"},{"key":"3605_CR4","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","volume":"18","author":"HA Tawbi","year":"2017","unstructured":"Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18:1493\u2013501.","journal-title":"Lancet Oncol"},{"key":"3605_CR5","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","volume":"19","author":"SP D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018;19:416\u201326.","journal-title":"Lancet Oncol"},{"key":"3605_CR6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575:299\u2013309.","journal-title":"Nature"},{"key":"3605_CR7","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.cell.2018.03.041","volume":"173","author":"C Kim","year":"2018","unstructured":"Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T, et al. Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing. Cell. 2018;173:879\u201393.","journal-title":"Cell"},{"key":"3605_CR8","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1158\/2159-8290.CD-20-1375","volume":"11","author":"C Duy","year":"2021","unstructured":"Duy C, Li M, Teater M, Meydan C, Garrett-Bakelman FE, Lee TC, et al. Chemotherapy induces senescence-like resilient cells capable of initiating AML recurrence. Cancer Discov. 2021;11:1542\u201361.","journal-title":"Cancer Discov"},{"key":"3605_CR9","doi-asserted-by":"publisher","first-page":"eabe3445","DOI":"10.1126\/sciadv.abe3445","volume":"7","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wu J, Chen H, Yang Y, Xiao C, Yi X, et al. Genome-wide CRISPR-Cas9 screen identified KLF11 as a druggable suppressor for sarcoma cancer stem cell. Sci Adv. 2021;7:eabe3445.","journal-title":"Sci Adv"},{"key":"3605_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.omtn.2017.06.008","volume":"8","author":"H Jin","year":"2017","unstructured":"Jin H, Luo S, Wang Y, Liu C, Piao Z, Xu M, et al. miR-135b stimulates osteosarcoma recurrence and lung metastasis via Notch and Wnt\/\u03b2-catenin signaling. Mol Ther Nucleic Acids. 2017;8:111\u201322.","journal-title":"Mol Ther Nucleic Acids"},{"key":"3605_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/srep22288","volume":"6","author":"K Maeda","year":"2016","unstructured":"Maeda K, Enomoto A, Hara A, Asai N, Kobayashi T, Horinouchi A, et al. Identification of meflin as a potential marker for mesenchymal stromal cells. Sci Rep. 2016;6:22288.","journal-title":"Sci Rep"},{"key":"3605_CR12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/gtc.12855","volume":"26","author":"A Hara","year":"2021","unstructured":"Hara A, Kato K, Ishihara T, Kobayashi H, Asai N, et al. Meflin defines mesenchymal stem cells and\/or their early progenitors with multilineage differentiation capacity. Genes Cells. 2021;26:495\u2013512.","journal-title":"Genes Cells"},{"key":"3605_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.749924","volume":"9","author":"M Takahashi","year":"2021","unstructured":"Takahashi M, Kobayashi H, Mizutani Y, Hara A, Iida T, et al. Roles of the Mesenchymal Stromal\/Stem Cell Marker Meflin\/Islr in Cancer Fibrosis. Front Cell Dev Biol. 2021;9:749924.","journal-title":"Front Cell Dev Biol"},{"key":"3605_CR14","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/cas.14346","volume":"111","author":"Y Miyai","year":"2020","unstructured":"Miyai Y, Esaki N, Takahashi M, Enomoto A. Cancer-associated fibroblasts that restrain cancer progression: Hypotheses and perspectives. Cancer Sci. 2020;111:1047\u201357.","journal-title":"Cancer Sci"},{"key":"3605_CR15","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1634\/stemcells.2005-0620","volume":"25","author":"J Tolar","year":"2007","unstructured":"Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, Bell S, et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells. 2007;25:371\u20139.","journal-title":"Stem Cells"},{"key":"3605_CR16","doi-asserted-by":"publisher","first-page":"4970","DOI":"10.1038\/onc.2012.507","volume":"32","author":"R Rubio","year":"2013","unstructured":"Rubio R, Gutierrez-Aranda I, S\u00e1ez-Castillo AI, Labarga A, Rosu-Myles M, Gonzalez-Garcia S, et al. The differentiation stage of p53-Rb-deficient bone marrow mesenchymal stem cells imposes the phenotype of in vivo sarcoma development. Oncogene. 2013;32:4970\u201380.","journal-title":"Oncogene"},{"key":"3605_CR17","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1158\/0008-5472.CAN-19-0454","volume":"79","author":"Y Mizutani","year":"2019","unstructured":"Mizutani Y, Kobayashi H, Iida T, Asai N, Masamune A, Hara A, et al. Meflin-positive cancer-associated fibroblasts inhibit pancreatic carcinogenesis. Cancer Res. 2019;79:5367\u201381.","journal-title":"Cancer Res"},{"key":"3605_CR18","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1038\/s41388-022-02288-9","volume":"41","author":"T Iida","year":"2022","unstructured":"Iida T, Mizutani Y, Esaki N, Ponik SM, Burkel BM, Weng L, et al. Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics. Oncogene. 2022;41:2764\u201377.","journal-title":"Oncogene"},{"key":"3605_CR19","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1053\/j.gastro.2020.11.011","volume":"160","author":"H Kobayashi","year":"2021","unstructured":"Kobayashi H, Gieniec KA, Wright JA, Wang T, Asai N, Mizutani Y, et al. The balance of stromal BMP signaling mediated by GREM1 and ISLR drives colorectal carcinogenesis. Gastroenterology. 2021;160:1224\u201339.","journal-title":"Gastroenterology"},{"key":"3605_CR20","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1161\/CIRCRESAHA.119.314806","volume":"125","author":"A Hara","year":"2019","unstructured":"Hara A, Kobayashi H, Asai N, Saito S, Higuchi T, Kato K, et al. Roles of the mesenchymal stromal\/stem cell marker meflin in cardiac tissue repair and the development of diastolic dysfunction. Circ Res. 2019;125:414\u201330.","journal-title":"Circ Res"},{"key":"3605_CR21","doi-asserted-by":"publisher","first-page":"e202101230","DOI":"10.26508\/lsa.202101230","volume":"5","author":"Y Miyai","year":"2022","unstructured":"Miyai Y, Sugiyama D, Hase T, Asai N, Taki T, Nishida K, et al. Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade. Life Sci Alliance. 2022;5:e202101230.","journal-title":"Life Sci Alliance"},{"key":"3605_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07638-4","volume":"9","author":"K Zhang","year":"2018","unstructured":"Zhang K, Zhang Y, Gu L, Lan M, Liu C, et al. Islr regulates canonical Wnt signaling-mediated skeletal muscle regeneration by stabilizing Dishevelled-2 and preventing autophagy. Nat Commun. 2018;9:5129.","journal-title":"Nat Commun"},{"key":"3605_CR23","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2019103255","volume":"39","author":"J Xu","year":"2020","unstructured":"Xu J, Tang Y, Sheng X, Tian Y, Deng M, et al. Secreted stromal protein ISLR promotes intestinal regeneration by suppressing epithelial Hippo signaling. EMBO J. 2020;39:e103255.","journal-title":"EMBO J"},{"key":"3605_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-09331-5","volume":"12","author":"S Minatoguchi","year":"2022","unstructured":"Minatoguchi S, Saito S, Furuhashi K, Sawa Y, Okazaki M, Shimamura Y, et al. A novel renal perivascular mesenchymal cell subset gives rise to fibroblasts distinct from classic myofibroblasts. Sci Rep. 2022;12:5389.","journal-title":"Sci Rep"},{"key":"3605_CR25","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.leukres.2009.11.004","volume":"34","author":"DS Marques","year":"2010","unstructured":"Marques DS, Sandrini JZ, Boyle RT, Marins LF, Trindade GS. Relationships between multidrug resistance (MDR) and stem cell markers in human chronic myeloid leukemia cell lines. Leuk Res. 2010;34:757\u201362.","journal-title":"Leuk Res"},{"key":"3605_CR26","doi-asserted-by":"publisher","first-page":"6641","DOI":"10.1158\/0008-5472.CAN-16-3452","volume":"77","author":"A Yang","year":"2017","unstructured":"Yang A, Qin S, Schulte BA, Ethier SP, Tew KD, et al. MYC Inhibition Depletes Cancer Stem-like Cells in Triple-Negative Breast Cancer. Cancer Res. 2017;77:6641\u201350.","journal-title":"Cancer Res"},{"key":"3605_CR27","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1084\/jem.20110840","volume":"208","author":"A Kobayashi","year":"2011","unstructured":"Kobayashi A, Okuda H, Xing F, Pandey PR, Watabe M, Hirota S, et al. Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med. 2011;208:2641\u201355.","journal-title":"J Exp Med"},{"key":"3605_CR28","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.cell.2012.06.035","volume":"150","author":"H Gao","year":"2012","unstructured":"Gao H, Chakraborty G, Lee-Lim AP, Mo Q, Decker M, Vonica A, et al. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell. 2012;150:764\u201379.","journal-title":"Cell"},{"key":"3605_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51270-1","volume":"9","author":"R Sachdeva","year":"2019","unstructured":"Sachdeva R, Wu M, Johnson K, Kim H, Celebre A, Shahzad U, et al. BMP signaling mediates glioma stem cell quiescence and confers treatment resistance in glioblastoma. Sci Rep. 2019;9:14569.","journal-title":"Sci Rep"},{"key":"3605_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3892\/ijmm.2021.4981","volume":"48","author":"Y Guo","year":"2021","unstructured":"Guo Y, Zhu H, Li X, Ma C, Li Y, Sun T, et al. RepSox effectively promotes the induced differentiation of sheep fibroblasts into adipocytes via the inhibition of the TGF-\u03b21\/Smad pathway. Int J Mol Med. 2021;48:148.","journal-title":"Int J Mol Med"},{"key":"3605_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1471-230X-11-71","volume":"11","author":"L Cao","year":"2011","unstructured":"Cao L, Zhou Y, Zhai B, Liao J, Xu W, et al. Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines. BMC Gastroenterol. 2011;11:71. https:\/\/doi.org\/10.1186\/1471-230X-11-71.","journal-title":"BMC Gastroenterol"},{"key":"3605_CR32","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/nbt832","volume":"21","author":"SO Doronina","year":"2003","unstructured":"Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21:778\u201384.","journal-title":"Nat Biotechnol"},{"key":"3605_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4149\/gpb_2022050","volume":"42","author":"T Ma","year":"2023","unstructured":"Ma T, Peng C, Wu D, Yang S, Ji L, Cheng Z, et al. Immune-based prognostic biomarkers associated with metastasis of osteosarcoma. Gen Physiol Biophys. 2023;42:1\u201312.","journal-title":"Gen Physiol Biophys"},{"key":"3605_CR34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature25167","volume":"553","author":"M Milanovic","year":"2018","unstructured":"Milanovic M, Fan DNY, Belenki D, D\u00e4britz JHM, Zhao Z, Yu Y, et al. Senescence-associated reprogramming promotes cancer stemness. Nature. 2018;553:96\u2013100.","journal-title":"Nature"},{"key":"3605_CR35","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1038\/sj.onc.1206366","volume":"22","author":"A Rebbaa","year":"2003","unstructured":"Rebbaa A, Zheng X, Chou PM, Mirkin BL. Caspase inhibition switches doxorubicin-induced apoptosis to senescence. Oncogene. 2003;22:2805\u201311.","journal-title":"Oncogene"},{"key":"3605_CR36","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama K, Anami Y, Ha SYY, Yamazaki CM. Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol. 2024;21:203\u201323.","journal-title":"Nat Rev Clin Oncol"},{"key":"3605_CR37","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/pbc.25099","volume":"61","author":"EA Kolb","year":"2014","unstructured":"Kolb EA, Gorlick R, Billups CA, Hawthorne T, Kurmasheva RT, Houghton PJ, et al. Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2014;61:1816\u201321.","journal-title":"Pediatr Blood Cancer"},{"key":"3605_CR38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/pbc.25688","volume":"63","author":"D Geller","year":"2016","unstructured":"Geller D, Houghton P, Kolb EA, Hawthorne T, Gill J, Gorlick R. Targeting glycoprotein NMB with antibody-drug cConjugate, Glembatumumab Vedotin, for the treatment of osteosarcoma. Pediatr Blood Cancer. 2016;63:32\u20138.","journal-title":"Pediatr Blood Cancer"},{"key":"3605_CR39","unstructured":"ClinicalTrails.gov Identifier: NCT02487979 (https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02487979?term=GPNMB&cond=Osteosarcoma&draw=2&rank=1)."},{"key":"3605_CR40","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1158\/0008-5472.CAN-18-0327","volume":"78","author":"JW Purcell","year":"2018","unstructured":"Purcell JW, Tanlimco SG, Hickson J, Fox M, Sho M, Durkin L, et al. LRRC15 is a novel mesenchymal protein and stromal target for antibody-drug conjugates. Cancer Res. 2018;78:4059\u201372.","journal-title":"Cancer Res"},{"key":"3605_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28771","volume":"68","author":"KK Slemmons","year":"2021","unstructured":"Slemmons KK, Mukherjee S, Meltzer P, Purcell JW, Helman LJ. LRRC15 antibody-drug conjugates show promise as osteosarcoma therapeutics in preclinical studies. Pediatr Blood Cancer. 2021;68:e28771.","journal-title":"Pediatr Blood Cancer"},{"key":"3605_CR42","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1158\/1078-0432.CCR-20-4513","volume":"27","author":"GD Demetri","year":"2021","unstructured":"Demetri GD, Luke JJ, Hollebecque A, Powderly JD 2nd, Spira AI, et al. First-in-human phase I study of ABBV-085, an antibody-drug conjugate targeting LRRC15, in sarcomas and other advanced solid tumors. Clin Cancer Res. 2021;27:3556\u201366.","journal-title":"Clin Cancer Res"},{"key":"3605_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20059-6","volume":"11","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Yang D, Yang Q, Lv X, Huang W, Zhou Z, et al. Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma. Nat Commun. 2020;11:6322.","journal-title":"Nat Commun"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03605-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03605-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03605-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T23:02:33Z","timestamp":1763420553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03605-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":43,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2025,12,9]]}},"alternative-id":["3605"],"URL":"https:\/\/doi.org\/10.1038\/s41388-025-03605-8","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"31 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.E. received a research grant from BFACT Co., Ltd.; N.E., M.M., M.T., and A.E. are founders of BFACT Co., Ltd.; N.E. is a representative of BFACT Co., Ltd.; Nagoya University licensed a patent relating to anti-Meflin antibody-drug conjugates to BFACT Co., Ltd. in 2021.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}